CONMED adds Kim Kelderman to board of directors

CONMED Corporation (NYSE: CNMD) announced that Kim Kelderman will join its board of directors effective September 8, 2025.

Kelderman currently serves as president, chief executive officer, and board member of Bio-Techne (NASDAQ: TECH) since February 2024. He joined Bio-Techne in April 2018 as president of diagnostics and genomics, and served as chief operating officer from November 2023 to January 2024.

Prior to Bio-Techne, Kelderman worked at Thermo Fisher Scientific, where he led three different businesses and managed the platforms and content of the genetic sciences division. His responsibilities included instrumentation, software, consumables and assays businesses, including brands such as Applied Biosystems and legacy Affymetrix.

Before joining Thermo Fisher, Kelderman served as senior segment leader at Becton Dickinson, managing the global blood tubes "Vacutainer" business. He holds a bachelor of science degree from Hogeschool Heerlen of Applied Sciences in the Netherlands.

"Kim brings extensive global leadership experience across life sciences businesses, with a strong track record in innovation and strategy," said LaVerne Council, chair of CONMED's board of directors.

CONMED is a medical technology company that provides devices and equipment for surgical procedures in specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology.

You May Also Be Interested In